Therapeutic Drug Monitoring News and Research

RSS

Bio-Techne to acquire 100% ownership of Cliniqa

Bio-Techne Corporation announced today that it has agreed to acquire 100% ownership of Cliniqa Corporation. Cliniqa specializes in the manufacturing and commercialization of quality controls and calibrators as well as bulk reagents used in the clinical diagnostic market.

From CLINIQA - Diagnostics Division 5 Jun 2015

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.

1 Jun 2015

Slug flow microextraction method for drug testing yields results in one minute

A new technique makes it possible to quickly detect the presence of drugs or to monitor certain medical conditions using only a single drop of blood or urine, representing a potential tool for clinicians and law enforcement.

10 Oct 2014

Carbon nanotube paper offers potential to miniaturize mass spectrometers

Nanotechnology is advancing tools likened to Star Trek's "tricorder" that perform on-the-spot chemical analysis for a range of applications including medical testing, explosives detection and food safety.

27 Mar 2014

New, effective and less toxic therapeutic option for patients with HER2-positive breast cancer

Patients with HER2-positive breast cancer, a particularly aggressive form of breast cancer, now have a new, effective and less toxic therapeutic option.

24 Feb 2013

Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Thermo Scientific QMS Everolimus Assay Kit has been CE marked for sale in the European Union for a third application, namely liver transplants.

From Thermo Fisher Scientific Inc. 16 Jan 2013

Bruker introduces Toxtyper clinical mass spectrometry solution

At the annual conference of the DGKL, Bruker today announced the European launch of the novel, automated Toxtyper clinical mass spectrometry solution to meet the increasing demands for LC-MS/MS throughput and data quality in routine toxicology laboratories without the need for mass spectrometry expertise.

26 Sep 2012

Saladax increases claims in immunoassay space to 15 patents

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that it has been issued six patents within the last 12 months, bringing the company's total to 15 issued U.S. patents, all of which contain broad claims in the immunoassay space.

11 Jan 2012

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

UCSD selects Millennium Labs, Research Institute for NIAAA granted study

Millennium Laboratories, a leading provider of therapeutic drug monitoring, research and healthcare education, and the Millennium Research Institute, a national non-profit research center, announced today they have been selected by the University of California, San Diego School of Medicine to provide laboratory services, including research and analysis, for a new UC San Diego study funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

22 Mar 2011

NMS Labs launches unique test for Methotrexate

NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy and helping physicians with therapeutic drug monitoring of patients for the therapeutic agent, Methotrexate.

8 Feb 2011

UnitedHealthcare selects Millennium as participating provider of pain management services

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced it will provide pain management and therapeutic drug monitoring services to physicians participating in UnitedHealthcare's national care provider network.

12 Jan 2011

SAGE launches two new journals in Drug Safety, Hematology

SAGE Expands Therapeutic Advances series by launching two new journals in Drug Safety and Hematology. SAGE has extended its suite of Therapeutic Advances journals with the launch of a further two titles: Therapeutic Advances in Drug Safety, and Therapeutic Advances in Hematology.

3 Dec 2010

Forensic Fluids Laboratories ranked #167th on Inc. 500 fastest growing companies list

Forensic Fluids Laboratories Inc., a leading provider of oral fluid drug testing, today announced that the company was named to the prestigious Inc. 500 list, a list of the most entrepreneurial and fastest growing companies in the United States. Forensic Fluids Lab was number 167 on the general list, number 10 in health care, number 2 in Michigan, and number 20 for women-owned.

31 Aug 2010

Millennium Laboratories signs agreement to assist physicians with drug monitoring services, tools

Millennium Laboratories, Inc., a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced today a national agreement with MultiPlan, the nation's leading comprehensive provider of healthcare cost management solutions. As a participating provider in the PHCS and MultiPlan Networks, Millennium Laboratories will assist participating physicians with state-of-the-art therapeutic drug monitoring services and tools.

9 Aug 2010

Millennium Laboratories urges for increase in physician reimbursement for POC urine drug screening

Millennium Laboratories, Inc., a national, research-based medication monitoring company specifically focused on clinicians who treat chronic pain, strongly advocated for an increase in physician reimbursement for point-of-care urine drug screening at the Annual Clinical Laboratory Public Meeting of the Centers for Medicare and Medicaid Services on July 22, 2010.

27 Jul 2010

Waters to present MassTrak solutions at American Association of Clinical Chemistry annual meeting

Waters Corporation is showcasing its portfolio of MassTrak solutions at the American Association of Clinical Chemistry annual meeting and Clinical Lab Expo July 25 - 29, 2010 in Anaheim in exhibit booth #4447. Waters portfolio of MassTrak Solutions for the clinical laboratory combines the power of separations science, tandem mass spectrometry, specialized chemistries, software, and support services in ways designed to optimize laboratory processes.

27 Jul 2010

NMS Labs launches test to evaluate the efficacy of Milnacipran

NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy, the potential for physicians to establish therapeutic drug monitoring of individual patients, and the assessment of drug diversion of a new pain management drug therapy.

31 Mar 2010

Aetna selects Millennium Laboratories as national pain management services provider

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today a national agreement with Aetna, one of the nation’s leading diversified health care benefits companies that serves approximately 36.3 million people. Under the terms of the three-year ancillary services agreement which went into effect February 1, 2010, Millennium Laboratories’ will assist Aetna participating physicians nationwide with state-of-the-art therapeutic drug monitoring services and tools.

23 Feb 2010

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

Response Biomedical Corporation announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a continuation of the patent entitled “Sensitive Immunochromatographic Assay”. This patent covers key aspects of Response Biomedical’s lateral flow immunoassays with the proprietary RAMP® testing platform.

21 Dec 2009